Receive alerts in your inbox.
Biotech and pharmaceutical companies turn to him for patent guidance at all stages of their company life cycle. Mark’s work for clients ranges from preparing initial patent applications to extending a patent’s value, and he has represented a number of major pharmaceutical and biotech companies.
Mark Pino is a Partner in Womble Carlyle’s Intellectual Property Practice Group in the firm’s Washington, DC office. Mr. Pino’s practice focuses on strategic patent portfolio management and counseling for domestic and foreign clients, primarily in the pharmaceutical, biotechnology, and chemical areas.
Mr. Pino has extensive experience working with biopharma clients in all phases of their business, starting from a first patent application, building to the management of international patent portfolios, and extending to the optimization of a product’s life cycle. In his practice Mr. Pino prepares patent applications and responses to office actions, represents clients in reexamination and reissue proceedings, and drafts briefs and present arguments to appeal boards. Mr. Pino also prosecutes patent term extension requests, seeks supplementary protection certificates, and advises on Orange Book listings submitted to the FDA.
In 2011, Mr. Pino was selected by Patent Buddy as one of the Top Patent Prosecutors nationally in the pharmaceutical/biotechnology area.
Representative clients include Bristol-Myers Squibb, Amylin Pharmaceuticals, AstraZeneca LLP, Hoffmann-LaRoche AG, Anadys Pharmaceuticals, and NPS Pharmaceuticals, wherein Mr. Pino manages the patent portfolios for Byetta®, Bydureon®, Symlin®, Sensipar®, Setrobuvir, and numerous other drug candidates in various phases of development or clinical trials. He has also led or responded to many due diligence investigations involving these clients.
Mr. Pino regularly participates in contentious proceedings before the United States Patent and Trademark Office, patent oppositions before the European Patent Office, and patent annullity/infringement actions in foreign forums. He often works closely with recognized experts to prepare declarations or offer testimony in various legal forums.
Earlier in his career Mr. Pino was involved in patent litigation, including significant experience with ANDA litigations and Section 337 proceedings before the International Trade Commission.
Mr. Pino’s technical background covers subject matter involving pharmaceuticals, small molecule and protein formulations (including delayed-release, polymer matrixes), peptides, crystalline forms, syringes, transdermal delivery, implantable devices, manufacturing processes, cell and biochemical assays, inorganics, and polymers. Prior to becoming a patent attorney, he worked as a medicinal chemist at Agouron Pharmaceuticals, and contributed to the discovery of Viracept®, an anti-HIV inhibitor.